Cidara Therapeutics, Inc.
CDTXCidara Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative antifungal and antiviral medicines. The company's portfolio includes therapies aimed at addressing serious infectious diseases, with an emphasis on immunocompromised and immunosuppressed patient populations. Cidara leverages novel delivery platforms and targeted approaches to improve treatment outcomes in difficult-to-treat infections.
Company News
Merck's stock has experienced significant volatility, dropping from $130 to $76 and rebounding to around $100. Despite concerns about Keytruda's patent expiration in 2028, the company shows potential through new drug developments, acquisitions, and a promising pharmaceutical pipeline.
Law firm Halper Sadeh LLC is investigating potential securities law violations and breaches of fiduciary duties for three companies involved in recent merger and acquisition transactions.
Pfizer's Phase 3 study reveals a new nucleoside-modified mRNA influenza vaccine with 34.5% relative efficacy against flu strains, showing superior protection compared to traditional vaccines, though with higher short-term side effects.
Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.66% and 26.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Penny stocks to watch before next week. The post 7 Top Penny Stocks Under $5; Time To Buy Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
